Skip to main navigation Investors PRESS RELEASE AMARIN TO PRESENT AT TWO INVESTOR CONFERENCES IN JUNE 2021 May 18, 2021 at 6:05 AM EDT PDF Version DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Karim Mikhail, Amarin’s senior vice president and head of commercial for Europe and future president and chief executive officer, are scheduled to present at the following investor conferences scheduled in June: Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 9:30 a.m. Eastern Time Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 10:30 a.m. Eastern Time Live audio webcasts of the presentations will be available at: http://www.amarincorp.com, and will be accessible at the same link for 30 days. About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management. Availability of Other Information About Amarin Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Amarin Contact Information Investor Inquiries: Investor Relations Amarin Corporation plc IR@amarincorp.com (investor inquiries) Solebury Trout amarinir@troutgroup.com Media Inquiries: Communications Amarin Corporation plc In U.S.: +1 (908) 892-2028 PR@amarincorp.com (media inquiries) Shareholder Tools PRINTED MATERIALS EMAIL ALERTS RSS SEARCH © 2021 Amarin Corporation All rights reserved. Disclaimer Privacy Policy Contact Us Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bridgewater, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN"). AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.